The results demonstrate that the combination treatment exhibited stronger inhibition of the colony forming ability than a single agent, and indicate the benefit and rationale to block both MEK and STAT3 oncogenic pathways in K-Ras mutant pancreatic cancer cells. Here, KRAS is linked to familial pancreatic carcinoma.